NewAmsterdam Pharma Company N.V. — Revenue by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/09a03b66-889b-45de-9df8-591f093794b6/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $22.5M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-056029 |
| FY 2024 | $45.6M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-027339 |
| FY 2023 | $14.1M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-021668 |
| FY 2022 | $102.7M | 2022-01-01 – 2022-12-31 | evidence 0000950170-24-021668 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
NewAmsterdam Pharma Company N.V. — all facts · Net Income · Operating Income